Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective.

Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG, Zivadinov R.

Vaccines (Basel). 2020 Jan 28;8(1). pii: E50. doi: 10.3390/vaccines8010050. Review.

2.

Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy.

Jakimovski D, Zivadinov R, Weinstock-Guttman B, Bergsland N, Dwyer MG, Lagana MM.

Fluids Barriers CNS. 2020 Jan 31;17(1):9. doi: 10.1186/s12987-020-0172-3.

3.

Recovery of cognitive function after relapse in multiple sclerosis.

Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S, Tacca B, Drake A, Wojcik C, Morrow SA, Jakimovski D, Fuchs TA, Dwyer MG, Zivadinov R, Weinstock-Guttman B.

Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108. [Epub ahead of print]

PMID:
31971066
4.

A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.

Tavazzi E, Bergsland N, Kuhle J, Jakimovski D, Ramanathan M, Maceski AM, Tomic D, Hagemeier J, Kropshofer H, Leppert D, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

J Neurol. 2019 Nov 25. doi: 10.1007/s00415-019-09643-z. [Epub ahead of print]

PMID:
31768628
5.

Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Bergsland N, Tavazzi E, Schweser F, Jakimovski D, Hagemeier J, Dwyer MG, Zivadinov R.

CNS Drugs. 2019 Nov;33(11):1073-1086. doi: 10.1007/s40263-019-00668-6.

PMID:
31556017
6.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

Radiology. 2019 Nov;293(2):424-433. doi: 10.1148/radiol.2019190306. Epub 2019 Sep 24.

PMID:
31549947
7.

Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis.

Fuchs TA, Benedict RHB, Bartnik A, Choudhery S, Li X, Mallory M, Oship D, Yasin F, Ashton K, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Hum Brain Mapp. 2019 Dec 15;40(18):5231-5241. doi: 10.1002/hbm.24768. Epub 2019 Aug 24.

PMID:
31444887
8.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Ann Clin Transl Neurol. 2019 Sep;6(9):1757-1770. doi: 10.1002/acn3.50872. Epub 2019 Aug 22. Erratum in: Ann Clin Transl Neurol. 2019 Dec;6(12):2607.

9.

Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D.

Neurology. 2019 Aug 6;93(6):e611-e623. doi: 10.1212/WNL.0000000000007892. Epub 2019 Jul 8.

PMID:
31285398
10.

Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R.

J Neuroimaging. 2019 Sep;29(5):615-623. doi: 10.1111/jon.12650. Epub 2019 Jul 1.

PMID:
31259467
11.

Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study.

Fuchs TA, Ziccardi S, Dwyer MG, Charvet LE, Bartnik A, Campbell R, Escobar J, Hojnacki D, Kolb C, Oship D, Pol J, Shaw MT, Wojcik C, Yasin F, Weinstock-Guttman B, Zivadinov R, Benedict RHB.

Mult Scler Relat Disord. 2019 Sep;34:103-111. doi: 10.1016/j.msard.2019.06.026. Epub 2019 Jun 22.

PMID:
31254960
12.

Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRI-based Decoupling of Complex Relationships.

Zivadinov R, Dwyer MG.

Radiology. 2019 Aug;292(2):458-459. doi: 10.1148/radiol.2019191125. Epub 2019 Jun 25. No abstract available.

PMID:
31237815
13.

Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.

Fuchs TA, Benedict RH, Wilding G, Wojcik C, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605. [Epub ahead of print]

PMID:
31219390
14.

Aging and Brain Atrophy in Multiple Sclerosis.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10.

PMID:
31074192
15.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.

16.

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.

Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.

AJNR Am J Neuroradiol. 2019 Mar;40(3):446-452. doi: 10.3174/ajnr.A5987. Epub 2019 Feb 28.

PMID:
30819766
17.

Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.

Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R.

J Neurol. 2019 Apr;266(4):866-875. doi: 10.1007/s00415-019-09208-0. Epub 2019 Feb 13.

PMID:
30758665
18.

Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.

Jakimovski D, Ramanathan M, Weinstock-Guttman B, Bergsland N, Ramasamay DP, Carl E, Dwyer MG, Zivadinov R.

Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667. [Epub ahead of print]

PMID:
30755085
19.

Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.

Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S.

J Comp Eff Res. 2019 Apr;8(5):305-316. doi: 10.2217/cer-2018-0135. Epub 2019 Feb 13.

20.

Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.

Fuchs TA, Wojcik C, Wilding GE, Pol J, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Benedict RH.

Mult Scler. 2020 Feb;26(2):245-252. doi: 10.1177/1352458518820272. Epub 2019 Jan 7.

PMID:
30615562
21.

Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis.

Zivadinov R, Bergsland N, Dwyer MG.

Quant Imaging Med Surg. 2018 Nov;8(10):979-983. doi: 10.21037/qims.2018.11.01. No abstract available.

22.

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.

Vaughn CB, Kavak KS, Dwyer MG, Bushra A, Nadeem M, Cookfair DL, Ramanathan M, Benedict RH, Zivadinov R, Goodman A, Krupp L, Motl RW, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Mult Scler. 2020 Jan;26(1):99-108. doi: 10.1177/1352458518816619. Epub 2018 Dec 3.

PMID:
30507270
23.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

24.

Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures.

Fuchs TA, Vaughn CB, Benedict RHB, Weinstock-Guttman B, Choudhery S, Carolus K, Rooney P, Ashton K, P Ramasamy D, Jakimovski D, Zivadinov R, Dwyer MG.

Mult Scler Relat Disord. 2019 Jan;27:298-304. doi: 10.1016/j.msard.2018.11.005. Epub 2018 Nov 9.

PMID:
30453198
25.

Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls.

Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F.

Neuroimage. 2019 Feb 1;186:308-320. doi: 10.1016/j.neuroimage.2018.11.011. Epub 2018 Nov 14.

26.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
27.

Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.

Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R.

J Neurol Sci. 2018 Oct 15;393:128-134. doi: 10.1016/j.jns.2018.08.020. Epub 2018 Aug 23.

PMID:
30165291
28.

Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage.

Zivadinov R, Polak P, Schweser F, Bergsland N, Hagemeier J, Dwyer MG, Ramasamy DP, Baker JG, Leddy JJ, Willer BS.

J Head Trauma Rehabil. 2018 Sep/Oct;33(5):E24-E32. doi: 10.1097/HTR.0000000000000422.

29.

Reply: Don't Leave the Back Door Open.

Dwyer MG, Lazar RM, Zivadinov R.

JACC Cardiovasc Interv. 2018 Jul 23;11(14):1420. doi: 10.1016/j.jcin.2018.05.011. No abstract available.

30.

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.

Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F.

Radiology. 2018 Nov;289(2):487-496. doi: 10.1148/radiol.2018180136. Epub 2018 Jul 17.

31.

Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.

Lin F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, Vaughn C, Gandhi S, Jakimovski D, Hulst HE, Benedict RH, Bergsland N, Fuchs T, Dwyer MG.

Mult Scler. 2019 Aug;25(9):1243-1254. doi: 10.1177/1352458518788218. Epub 2018 Jul 13.

PMID:
30004291
32.

Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study.

Fuchs TA, Carolus K, Benedict RHB, Bergsland N, Ramasamy D, Jakimovski D, Weinstock-Guttman B, Kuceyeski A, Zivadinov R, Dwyer MG.

AJNR Am J Neuroradiol. 2018 Aug;39(8):1480-1486. doi: 10.3174/ajnr.A5720. Epub 2018 Jul 5.

33.

Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study.

Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

Hum Brain Mapp. 2018 Oct;39(10):4007-4017. doi: 10.1002/hbm.24227. Epub 2018 Jun 19.

34.

Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2018 Sep;28(5):490-495. doi: 10.1111/jon.12527. Epub 2018 Jun 1.

PMID:
29856910
35.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
36.

White matter tract network disruption explains reduced conscientiousness in multiple sclerosis.

Fuchs TA, Dwyer MG, Kuceyeski A, Choudhery S, Carolus K, Li X, Mallory M, Weinstock-Guttman B, Jakimovski D, Ramasamy D, Zivadinov R, Benedict RHB.

Hum Brain Mapp. 2018 Sep;39(9):3682-3690. doi: 10.1002/hbm.24203. Epub 2018 May 8.

PMID:
29740964
37.

Establishing pathological cut-offs for lateral ventricular volume expansion rates.

Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R.

Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018.

38.

The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.

Uher T, Krasensky J, Sobisek L, Seidl Z, Bergsland N, Dwyer MG, Kubala Havrdova E, Zivadinov R, Horakova D, Vaneckova M.

J Neuroimaging. 2018 May;28(3):328-337. doi: 10.1111/jon.12505. Epub 2018 Feb 27.

PMID:
29485230
39.

Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis.

Zivadinov R, Ramasamy DP, Hagemeier J, Kolb C, Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Hojnacki D.

AJNR Am J Neuroradiol. 2018 Apr;39(4):642-647. doi: 10.3174/ajnr.A5541. Epub 2018 Feb 8.

40.

Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement: Insights From the SENTINEL Trial.

Lazar RM, Pavol MA, Bormann T, Dwyer MG, Kraemer C, White R, Zivadinov R, Wertheimer JC, Thöne-Otto A, Ravdin LD, Naugle R, Mechanic-Hamilton D, Garmoe WS, Stringer AY, Bender HA, Kapadia SR, Kodali S, Ghanem A, Linke A, Mehran R, Virmani R, Nazif T, Parhizgar A, Leon MB.

JACC Cardiovasc Interv. 2018 Feb 26;11(4):384-392. doi: 10.1016/j.jcin.2017.10.041. Epub 2018 Feb 1.

41.

Longitudinal personality change associated with cognitive decline in multiple sclerosis.

Roy S, Drake A, Fuchs T, Dwyer MG, Zivadinov R, Chapman BP, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720. [Epub ahead of print]

PMID:
29363385
42.

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals.

Hagemeier J, Ramanathan M, Schweser F, Dwyer MG, Lin F, Bergsland N, Weinstock-Guttman B, Zivadinov R.

Neuroimage Clin. 2017 Nov 8;17:530-540. doi: 10.1016/j.nicl.2017.11.003. eCollection 2018.

43.

Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.

Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D; MS-MRIUS Study Group.

AJNR Am J Neuroradiol. 2018 Feb;39(2):289-295. doi: 10.3174/ajnr.A5442. Epub 2017 Nov 23.

44.

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.

Bergsland N, Horakova D, Dwyer MG, Uher T, Vaneckova M, Tyblova M, Seidl Z, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Nov 5;17:444-451. doi: 10.1016/j.nicl.2017.11.002. eCollection 2018.

45.

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Uher T, Vaneckova M, Krasensky J, Sobisek L, Tyblova M, Volna J, Seidl Z, Bergsland N, Dwyer MG, Zivadinov R, De Stefano N, Sormani MP, Havrdova EK, Horakova D.

Mult Scler. 2019 Apr;25(4):541-553. doi: 10.1177/1352458517742739. Epub 2017 Nov 16.

PMID:
29143562
46.

Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality.

Schweser F, Raffaini Duarte Martins AL, Hagemeier J, Lin F, Hanspach J, Weinstock-Guttman B, Hametner S, Bergsland N, Dwyer MG, Zivadinov R.

Neuroimage. 2018 Feb 15;167:438-452. doi: 10.1016/j.neuroimage.2017.10.063. Epub 2017 Oct 31.

47.

Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.

Modica CM, Schweser F, Sudyn ML, Bertolino N, Preda M, Polak P, Siebert DM, Krawiecki JC, Sveinsson M, Hagemeier J, Dwyer MG, Pol S, Zivadinov R.

PLoS One. 2017 Aug 10;12(8):e0182729. doi: 10.1371/journal.pone.0182729. eCollection 2017.

48.

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.

Dwyer MG, Silva D, Bergsland N, Horakova D, Ramasamy D, Durfee J, Vaneckova M, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Jun 19;15:769-779. doi: 10.1016/j.nicl.2017.06.022. eCollection 2017.

49.

Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease.

Woodward MR, Dwyer MG, Bergsland N, Hagemeier J, Zivadinov R, Benedict RH, Szigeti K.

Psychiatry Res Neuroimaging. 2017 Aug 30;266:90-95. doi: 10.1016/j.pscychresns.2017.06.004. Epub 2017 Jun 9.

50.

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

Uher T, Krasensky J, Vaneckova M, Sobisek L, Seidl Z, Havrdova E, Bergsland N, Dwyer MG, Horakova D, Zivadinov R.

J Neuroimaging. 2017 Nov;27(6):620-629. doi: 10.1111/jon.12445. Epub 2017 May 2.

PMID:
28464417

Supplemental Content

Loading ...
Support Center